Employees: 172
Size 908 Devices (MASS) is a United States Health Care company (Medical Specialties) with a market value of $396M, the 2841st largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.52 on 18 Nov 2026.
Performance Over six months the shares gained 36.4%, against -25.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 14.1% over the last twelve months (peer median +14.5%); the operating margin is -33.2% (peer median 9.3%).
Valuation It trades at 4.6× enterprise value to sales against a peer median of 3.9× (8th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 42% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 40.0 points below its cost of capital (8.3% WACC).
Backlog Backlog (remaining performance obligations) was $22.9M at 30 Sep 2026, up 25% on a year earlier — 0.3 years of trailing revenue. Backlog detail →
Short interest Short interest is 6.2% of the free float (30 Oct 2026).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $65.8M | $56.2M | $47.7M | $50.2M | $46.9M |
| Revenue growth | — | +18% | -5% | +7% | — |
| Gross profit | $32.1M | $26.8M | $21.5M | $23.4M | $24.6M |
| EBITDA | -$16.7M | -$19.7M | -$25.3M | -$40.0M | -$33.6M |
| Net income | -$24.2M | -$36.6M | -$72.2M | -$36.4M | -$33.6M |
| Free cash flow | $2.50M | -$24.6M | -$30.8M | -$27.1M | -$23.0M |
| Capital expenditure | $261,000 | $955,000 | $602,000 | $2.04M | $2.04M |
| Total debt | $5.05M | $4.63M | $4.07M | $5.95M | $19.5M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MASS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.3% | -11.5% | 5th lowest of 21 |
| 6-month return | +36.4% | -25.6% | 2nd highest of 20 |
| Distance from 52-week high | -28.7% | -45.5% | 3rd highest of 21 |
| Revenue growth (TTM) | +14.1% | +14.5% | 11th highest of 21 |
| Operating margin | -33.2% | 9.3% | 5th lowest of 21 |
| EV / Sales | 4.6× | 3.9× | 8th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 41.7% | -2.2% | most demanding of 11 |
| Growth delivered (Del g) | +15.9% | +15.5% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | +25.8 pp | -2.0 pp | most demanding of 11 |
| ROIC minus cost of capital | -40.0 pp | -1.2 pp | 3rd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | 4.6× | 41.7% | +15.9% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | 7.1× | n/a | n/a |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 1.0× | -17.6% | +15.4% |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 5.5× | -6.3% | +247.0% |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | 1.8× | n/a | n/a |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | 1.7× | n/a | n/a |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 1.4× | n/a | n/a |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | 1.8× | -9.5% | -6.6% |
| Chison Medical Technologies 688358.SS | China | $406M | -27% | -1% | 19% | 3.9× | 9.6% | +5.6% |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 1.4× | -10.3% | +16.9% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 7.8× | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | 1.5× | 17.1% | +18.1% |
| Jenscare Scientific 9877.HK | Hong Kong | $415M | -32% | +993% | -106% | 17.8× | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | 218.3× | n/a | n/a |
| Ningbo Tianyi Medical Appliance 301097.SZ | China | $418M | -22% | +46% | 8% | 4.4× | n/a | n/a |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 1.8× | -4.2% | -6.0% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 4.8× | 24.9% | +18.8% |
| Hunan Sundy Science and Technology 300515.SZ | China | $425M | -16% | +10% | 27% | 3.5× | -0.1% | +15.6% |
| China Isotope & Radiation 1763.HK | Hong Kong | $428M | -41% | -5% | 13% | n/a | n/a | n/a |
| Revenio REG1V.HE | Finland | $428M | -34% | +44% | 10% | 4.0× | 18.5% | +12.4% |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | 24.8× | n/a | n/a |
908 Devices reported $22.9M of remaining performance obligations at 30 Sep 2026, up 25% from a year earlier and up 6% from the previous quarter. That is 0.3 years of trailing revenue already under contract. Book-to-bill last quarter: 1.06.